MXCT
Maxcyte·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MXCT
Maxcyte, Inc.
A British biotech company pioneering cell therapies for refractory cancers, leveraging its proprietary CAR-T technology
9713 Key West Avenue, Suite 400, Rockville, Maryland 20850
--
MaxCyte, Inc., was incorporated on July 31, 1998 under the laws and regulations of the State of Delaware. The company is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research and the discovery, development and commercialization of next-generation cell therapies. Over the past two decades, the company has developed and commercialized the proprietary Flow Electroporation platform, which facilitates complex engineering of various cells.
Earnings Call
Q1/2025
Estimate EPS-0.1
Actual EPS-0.1
Estimate Revenue9.05M
Actual Revenue10.40M
MaxCyte's Q1 2025 Earnings Call: Navigating Contradictions in Regulation, Growth, and Revenue Expectations
May 11,2025 12:13
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.1
Actual EPS-0.12
Estimate Revenue9.52M
Actual Revenue8.50M
MaxCyte's Q2 2025 Earnings Call: Unpacking Key Contradictions in Growth and Manufacturing Strategy
Aug 07,2025 03:55
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MXCT has released its 2025 Q3 earnings. EPS was reported at -0.12, versus the expected -0.1, missing expectations. The chart below visualizes how MXCT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MXCT has released its 2025 Q3 earnings report, with revenue of 6.83M, reflecting a YoY change of -16.35%, and net profit of -12.42M, showing a YoY change of -7.43%. The Sankey diagram below clearly presents MXCT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
